GAM
KPTI icon

Gotham Asset Management’s Karyopharm Therapeutics KPTI Stock Holding History

Gotham Asset Management’s Portfolio KPTI Stock Details KPTI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q1 		– Sell
-825
Closed -$237K – 1145
2019
Q4 		$237K Buy
+825
New +$179K ﹤0.01% 1006

Other funds holding KPTI

CCM
Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Alkeon Capital Management
Alkeon Capital Management New York $59.5B AUM 51.63% 1-Year Est. Return

Gotham Asset Management's KPTI Position: Q1 2020 in Review

Gotham Asset Management sold out of Karyopharm Therapeutics (KPTI) in Q1 2020, closing a stake of 825 shares — an estimated $237K sold.

Gotham Asset Management first reported a position in KPTI in Q4 2019 and held it in 1 quarter. The position peaked at $237K in Q4 2019. 136 funds tracked by Wall St. Rank hold KPTI as of Q1 2020.

  • Gotham Asset Management reported no remaining Karyopharm Therapeutics position as of Q1 2020 after selling out during the quarter.
  • Gotham Asset Management sold 825 Karyopharm Therapeutics shares in Q1 2020, an estimated $237K.
  • Gotham Asset Management first reported a position in Karyopharm Therapeutics in Q4 2019 and held it in 1 quarter.
  • Gotham Asset Management's Karyopharm Therapeutics position peaked at $237K in Q4 2019.
  • 136 funds tracked by Wall St. Rank held Karyopharm Therapeutics as of Q1 2020.

Based on Gotham Asset Management's 13F filing for Q1 2020, filed 15 May 2020.